Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669955 | 0.80 | FDPS (0.46) | PTPRAKDM4ECA2CA1LMNA | |
| SCHEMBL5884240 | 0.76 | FDPS (0.40) | PTPRACA2CA1LMNANAPRT | |
| SCHEMBL5670294 | 0.76 | FDPS (0.40) | PTPRACA2CA1LMNANAPRT | |
| SCHEMBL5750240 | 0.75 | FDPS (0.45) | KDM4ECA2CA1FDPSNPSR1 | |
| SCHEMBL5664700 | 0.75 | CA2 (0.50) | CA2LMNANPSR1KMT2ACA4 | |
| SCHEMBL29822627 | 0.74 | CA2 (0.54) | KDM4ECA2CA1LMNANAPRT | |
| SCHEMBL1400873 | 0.74 | CA2 (0.54) | KDM4ECA2CA1LMNANAPRT | |
| SCHEMBL5060264 | 0.73 | GGH (0.39) | PTPRAFDPSALDH1A1CYP1A2CYP2C19 | |
| Water SCHEMBL28253140 | 0.72 | CA2 (0.52) | KDM4ECA2CA1LMNANAPRT | |
| SCHEMBL26685804 | 0.72 | CA2 (0.64) | KDM4ECA2CA1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132427-B2 | Quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1463742-A4 | NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1412367-A4 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7019139-B2 | Quinolinones and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-7009054-B2 | Quinolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| EP-1408971-A4 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6960572-B2 | Indolinones and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1408978-A4 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6878697-B2 | Phenylamino-pyrimidines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242611-A1 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20030105115-A1 | Novel pyridopyrimidines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030105065-A1 | Novel quinolines and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | ARIAD PHARMACEUTICALS,INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030100573-A1 | Novel quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000187-A2 | NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000266-A1 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000251-A1 | NOVEL IDOLINONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000705-A1 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000011-A2 | NOVEL PYRIDOPYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000186-A2 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105065-A1 | Novel quinolines and uses thereof | UQCRB, RECQL, QTRT2 | PTPRA 4740/4885KDM4E 3193/4885CA2 3873/4885 |
| US-20040242611-A1 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | DPYD, TYMP, DDX41 | PTPRA 2602/4885KDM4E 2425/4885CA2 4814/4885 |
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | UQCRB, RRM2B, CYP2B6 | PTPRA 1445/4885KDM4E 3580/4885CA2 4602/4885 |
| US-20030105115-A1 | Novel pyridopyrimidines and uses thereof | DPYD, RRM2B, RRM2 | PTPRA 960/4885KDM4E 2965/4885CA2 4448/4885 |
| US-20030100573-A1 | Novel quinazolines and uses thereof | UQCRB, NQO2, RAB7A | PTPRA 4541/4885KDM4E 3990/4885CA2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.